The mRNA Revolution That Cured Cancer for Some Patients Is Coming for Everyone Else

Personalized mRNA cancer vaccines showed 44% reduction in recurrence in melanoma trials. Here is when they will be available, who they will work for, and what the technology actually does.

The mRNA technology that produced COVID-19 vaccines in record time has a second, more slowly developing application that is beginning to show results that oncologists are using the word 'revolution' to describe — carefully, knowing how often the word has been misapplied in cancer treatment history, but with a specificity that suggests this time the word may be warranted.

Personalised mRNA cancer vaccines work on a principle that is conceptually elegant: sequence the patient's tumour to identify the specific mutations that distinguish cancer cells from normal cells; manufacture an mRNA sequence encoding short protein fragments from those specific mutations; inject the mRNA so that the patient's immune cells learn to recognise the mutation-derived proteins; the immune system then attacks tumour cells displaying those proteins.

Moderna and Merck's Phase 3 trial of mRNA-4157 (V940) in combination with Keytruda for high-risk melanoma — reporting results in early 2026 — showed a 44 percent reduction in recurrence or death compared to Keytruda alone. For a cancer that kills approximately 7,000 Americans annually, a 44 percent improvement in recurrence-free survival is clinically extraordinary. The FDA has designated the combination for priority review, with approval decision expected mid-2026.

The technology's limits are real and must be stated to provide honest context. It works best in cancers that are highly mutated — melanoma, lung cancer, colorectal cancer — whose tumours contain many mutations that the immune system can be taught to attack. It works less well in cancers with few mutations, whose tumours present fewer immunological targets. And the manufacturing process — sequencing each patient's tumour, bioinformatically designing the optimal mRNA sequences, manufacturing a patient-specific vaccine — currently takes 6-8 weeks and costs approximately $200,000 per patient.

The scaling challenge is therefore the primary barrier between this proven technology and widespread access: manufacturing personalised vaccines for millions of cancer patients requires infrastructure that doesn't yet exist at that scale. The next five years of oncology investment will be substantially shaped by whether that infrastructure can be built.